Annals of Hematology

, Volume 85, Issue 2, pp 113–120 | Cite as

Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation

  • J. Vela-Ojeda
  • M. A. García-Ruiz Esparza
  • E. Reyes-Maldonado
  • L. Jiménez-Zamudio
  • E. García-Latorre
  • M. Moreno-Lafont
  • I. Estrada-García
  • L. Montiel-Cervantes
  • F. Tripp-Villanueva
  • M. Ayala-Sánchez
  • L. D. García-León
  • J. R. Borbolla-Escoboza
  • H. Mayani
Original Article


To analyze the relationship between the cellular composition of peripheral blood allografts and clinical outcome, we performed a prospective study in 45 adult patients who underwent allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, type 1 and type 2 dendritic cells (DC1 and DC2), as well as regulatory T (Treg) lymphocytes was analyzed. All patients were conditioned with busulphan and cyclophosphamide (BuCy2) ± VP-16 and received a short course of methotrexate and cyclosporin-A as graft-versus-host disease (GVHD) prophylaxis. Acute GVHD (aGVHD) was present in 9 of 43 (21%) patients, and chronic GVHD (cGVHD) developed in 18 of 39 (46%) patients. There was a significantly higher incidence of aGVHD in patients receiving more than 6×106/kg CD34+ cells. In univariate analysis, variables associated with better survival were as follows: a dose of less than 1.5×107/kg NKT cells and less than 1.7×106/kg DC2 for disease-free survival (DFS), and a dose of less than 3×107/kg NK cells, less than 1.5×107/kg NKT cells, less than 3×106/kg DC1, and less than 1.7×106/kg DC2 for overall survival (OS). In the Cox regression analysis, the dose of NKT cells was the only variable associated with better DFS, while the doses of NK, NKT, and CD34+ cells (less than 8×106/kg) were associated with better OS. In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT.


NK NKT Dendritic cells Regulatory T cells Stem cell transplantation Clinical outcome 


  1. 1.
    Little M, Storb R (2002). History of haematopoietic stem-cell transplantation. Nat Rev Cancer 2:231–238CrossRefPubMedGoogle Scholar
  2. 2.
    Wagner JE, Zahurak M, Piantadosi S, Geller RB, Vogelsang GB, Wingard JR, Saral R, Griffin C, Shah N, Zehnbauer BA (1992). Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. J Clin Oncol 10:779–789PubMedGoogle Scholar
  3. 3.
    Fefer A (1999) Hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ (eds) Blackwell Science, Malden, MA, pp 316–326Google Scholar
  4. 4.
    Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L et al (2004). Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3+ and CD4+ lymphocytes. Ann Hematol 83:295–301CrossRefPubMedGoogle Scholar
  5. 5.
    Parham P, McQueen KL (2003) Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 3:108–122CrossRefPubMedGoogle Scholar
  6. 6.
    Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Boiron JM, Schuller MP, Moatti JP, Michallet M (2000) Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 18:537–546PubMedGoogle Scholar
  7. 7.
    Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russel N, Apperley JF, Gorin NC, Szer J, Bradstock K, Buzyn A, Clack P, Borkett K, Gratwohl A; European Group for Blood and Marrow Transplantation (2002) Transplantation of mobilized peripheral blood cells to HLA identical siblings with standard risk leukemia. Blood 100:761–767CrossRefPubMedGoogle Scholar
  8. 8.
    Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, Van Beisen K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE (1995) Allogeneic blood stem cell transplantation: peripheralization and yield of donor derived primitive hematopoietic progenitor cells (CD34+Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86:2842–2848PubMedGoogle Scholar
  9. 9.
    Arat M, Arslan O, Gürman G, Dalva K, Ozcan M, Ugur A, Ilhan O (2004) The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy. Transfus Apher Sci 30:9–15CrossRefPubMedGoogle Scholar
  10. 10.
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828PubMedGoogle Scholar
  11. 11.
    Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T (1991) Chronic graft-versus host disease, other late complications of bone marrow transplantation. Semin Hematol 28:250–259PubMedGoogle Scholar
  12. 12.
    Gorin NC, Labopin M, Rocha V, Arcese W, Beksak M, Gluckman E, Ringden O, Ruutu T, Reiffers J, Bandini G, Falda M, Zikos P, Willemze R, Franssoni F; European Cooperative Group for Blood and Marrow Transplantation Acute Leukemia Working Party (2003) Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of the dose and stem cell source shows better outcome with rich marrow. Blood 102:3043–3051CrossRefPubMedGoogle Scholar
  13. 13.
    Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, Appelbaum FR, Bryant E, Vahauncey TR, Sale G, Sanders JE, Storb R, Sullivan KM, Anasetti C (1997) Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA matching and marrow cell dose. Blood 89:4226–4235PubMedGoogle Scholar
  14. 14.
    Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R, Martin PJ, Flowers ME, Storek J, Georges G, Storb R, Torok-Storb B (2001) CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98:3221–3227CrossRefPubMedGoogle Scholar
  15. 15.
    Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Korbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Anderson BS, Anderlini P, Champlin R (1999) Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 94:1465–1470PubMedGoogle Scholar
  16. 16.
    Heimfeld S (2003) Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation? Bone Marrow Transplant 17:856–858Google Scholar
  17. 17.
    Urbini B, Arpinati M, Bonifazi F, Chirumbolo G, Falcioni S, Stanzani M, Bandini G, Motta MR, Perone G, Giannini B, Tura S, Baccarani M, Rondelli D (2003) Allogeneic graft CD34+ cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant. Exp Hematol 31:953–958CrossRefPubMedGoogle Scholar
  18. 18.
    Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C, Millar B, Shepherd V, Tait D, Saso R, Rowland A, Long S, Mehta J (2000) A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2×106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 26:489–496CrossRefPubMedGoogle Scholar
  19. 19.
    Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A, Dal Cortivo L, Marolleau JP, Garnier F, Ribaud P, Gluckman E (2002) Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 99:2726–2733CrossRefPubMedGoogle Scholar
  20. 20.
    Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NK, Davies SM (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611–1618PubMedGoogle Scholar
  21. 21.
    Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640CrossRefPubMedGoogle Scholar
  22. 22.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ (1998) Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 101:1835–1842PubMedCrossRefGoogle Scholar
  23. 23.
    Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–3010CrossRefPubMedGoogle Scholar
  24. 24.
    Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan D, Parham P (2002) Genetic control of human NK-cell repertoire. J Immunol 169:239–247PubMedGoogle Scholar
  25. 25.
    Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A (2002) Defective expression and function of natural killer cells triggering receptors in patients with acute myeloid leukemia. Blood 99:3661–3667CrossRefPubMedGoogle Scholar
  26. 26.
    Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L Moretta A (2002) A major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178–6186PubMedGoogle Scholar
  27. 27.
    Pascal V, Brunet C, Pradel V, Thirion X, Andre P, Faucher C, Sampol J, Dignat-George F, Blaise D, Vivier E, Chabannon C (2002) Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation. Leukemia 16:2259–2266CrossRefPubMedGoogle Scholar
  28. 28.
    Yamasaki S, Henzan H, Ohno Y, Yamanaka T, Iino T, Itou Y, Kuroiwa M, Maeda M, Kawano N, Kinukawa N, Miyamoto T, Nagafuji K, Shimoda K, Inaba S, Hayashi S, Taniguchi S, Shibuya T, Gondo H, Otsuka T, Harada M; Fukuoka Blood and Marrow Transplantation Group (2003) Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant 32:505–510CrossRefPubMedGoogle Scholar
  29. 29.
    Miller JS, Prosper F, McCullar V (1997) Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood 90:3098–3105PubMedGoogle Scholar
  30. 30.
    Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI (2002) NKT cells—conductors of tumor immunity? Curr Opin Immunol 14:165–171CrossRefPubMedGoogle Scholar
  31. 31.
    Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, Strober S (1999) Bone marrow NK1.1− and NK1.1+ T cells reciprocally regulate acute graft versus host disease. J Exp Med 189:1073–1081CrossRefPubMedGoogle Scholar
  32. 32.
    Gansuvd B, Hagihara M, Yu Y, Inoue H, Ueda Y, Tsuchiya T, Masui A, Ando K, Nakamura Y, Munkhtuvshin N, Kato S, Thomas JM, Hotta T (2002) Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms. Hum Immunol 63:164–175CrossRefPubMedGoogle Scholar
  33. 33.
    Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, Tokunaga K, Suzuki K, Kayagaki N, Yagita H, Hirai H, Juji T (2001) TRAIL expression by activated human CD4+ Vα24NKT cells induces in vitro and in vivo apoptosis of human myeloid leukemia cells. Blood 97:2067–2074CrossRefPubMedGoogle Scholar
  34. 34.
    Linn YC, Lau LC, Kam Hui M (2002) Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116:78–86CrossRefPubMedGoogle Scholar
  35. 35.
    Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS (2001) Expansion of cytolytic CD8+ natural killer cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 97:2923–2931CrossRefPubMedGoogle Scholar
  36. 36.
    Arpinati M, Chirumbolo G, Urbini B, Perrone G, Rondelli D, Anasetti C (2003) Role of plasmocytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 11:345–356CrossRefPubMedGoogle Scholar
  37. 37.
    Waller EK, Rosenthal H, Jones TW, Peel J, Lonial S, Langston A, Redei I, Jurickova I, Boyer MW (2001) Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 97:2948–2956CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • J. Vela-Ojeda
    • 1
    • 2
  • M. A. García-Ruiz Esparza
    • 1
  • E. Reyes-Maldonado
    • 2
  • L. Jiménez-Zamudio
    • 2
  • E. García-Latorre
    • 2
  • M. Moreno-Lafont
    • 2
  • I. Estrada-García
    • 2
  • L. Montiel-Cervantes
    • 1
    • 2
  • F. Tripp-Villanueva
    • 1
  • M. Ayala-Sánchez
    • 1
  • L. D. García-León
    • 1
  • J. R. Borbolla-Escoboza
    • 3
  • H. Mayani
    • 4
  1. 1.Hematology Department, Stem Cell Transplant Program, Unidad Medica de Alta Especialidad “Antonio Fraga Mouret” National Medical Center “La Raza”Instituto Mexicano del Seguro SocialMéxicoMéxico
  2. 2.Escuela Nacional de Ciencias BiológicasInstituto Politécnico NacionalMexicoMexico
  3. 3.Bone Marrow Transplant Program, Hospital San José—Tec de Monterrey and Medical SchoolInstituto Tecnológico y de Estudios Superiores de MonterreyMonterreyMéxico
  4. 4.Oncological Research Unit, Oncology Hospital, National Medical CenterInstituto Mexicano del Seguro SocialMexicoMexico

Personalised recommendations